Evaluation of Gadolinium Based Contrast Agents for Portable MR Imaging Systems
← catalyst calendarSponsored by Hyperfine (industry) · HYPR — their whole pipeline →.
Phase
Not applicable
Status
Enrolling by invitation
Study type
Interventional
Design
Na · None · Other
Enrollment
85estimated
Sites
6
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-12-30 | actual | When the study began enrolling |
| Primary completion | 2026-07-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-10-31 | estimated | The whole study's end, after follow-up |
| First posted | 2025-12-22 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-15 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Intra-axial Tumors
- Extra-axial Tumors
- Infection/Inflammatory Lesions
Interventions
- Device: Portable MRI (pMRI)
- Drug: Gadolinium-Based Contrast Agent (GBCA)
Primary outcomes
what the primary-completion date above is the date OFRadiologist-rated lesion border delineation on post-contrast portable MRI
measured 6 months
Radiologist-rated lesion internal morphology visibility on post-contrast portable MRI
measured 6 months
Radiologist-rated degree of contrast enhancement of target lesions on portable MRI
measured 6 months
Permalink · HYPR's whole pipeline · Catalyst calendar · Every registered study · What changed